Sandoz Gets US Denosumab Approvals – But When Will They Launch?
FDA Also Grants Interchangeability Designation For First Biosimilars To Prolia And Xgeva
Sandoz has received the first FDA approvals for denosumab biosimilar rivals to Prolia and Xgeva under the names Wyost and Jubbonti. However, the firm has declined to comment on launch details while it remains locked in litigation with originator Amgen.
